$AKBA
Akebia Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016017968 Filed on May 05, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.800M $3.400M
YoY Change 70.59% -10.53%
% of Gross Profit
Research & Development $20.20M $7.500M
YoY Change 169.33% 21.79%
% of Gross Profit
Depreciation & Amortization $32.00K $19.00K
YoY Change 68.42% 137.5%
% of Gross Profit
Operating Expenses $26.05M $10.90M
YoY Change 139.04% 9.96%
Operating Profit -$26.05M -$10.90M
YoY Change 139.04% 9.96%
Interest Expense $200.0K $100.0K
YoY Change 100.0%
% of Operating Profit
Other Income/Expense, Net $248.0K $201.0K
YoY Change 23.38% -5.19%
Pretax Income -$25.80M -$10.70M
YoY Change 141.12% 10.31%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.80M -$10.70M
YoY Change 141.22% 10.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$699.2K -$535.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.4M $67.23M
YoY Change 147.54% -49.15%
Cash & Equivalents $43.44M $27.89M
Short-Term Investments $123.0M $39.34M
Other Short-Term Assets $2.500M $2.300M
YoY Change 8.7% 53.33%
Inventory
Prepaid Expenses
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $219.5M $102.7M
YoY Change 113.73% -23.21%
LONG-TERM ASSETS
Property, Plant & Equipment $600.0K $400.0K
YoY Change 50.0% 143.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $400.0K
YoY Change 225.0% 219.12%
Total Long-Term Assets $1.900M $800.0K
YoY Change 137.5% 176.29%
TOTAL ASSETS
Total Short-Term Assets $219.5M $102.7M
Total Long-Term Assets $1.900M $800.0K
Total Assets $221.4M $103.5M
YoY Change 113.91% -22.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $4.300M
YoY Change -44.19% 107.0%
Accrued Expenses $11.00M $4.500M
YoY Change 144.44% 11.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.40M $8.800M
YoY Change 52.27% 43.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $40.30M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $40.30M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.40M $8.800M
Total Long-Term Liabilities $40.30M $0.00
Total Liabilities $53.70M $8.900M
YoY Change 503.37% 44.46%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.8M $94.60M
YoY Change
Total Liabilities & Shareholders Equity $221.4M $103.5M
YoY Change 113.91% -22.78%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$25.80M -$10.70M
YoY Change 141.22% 10.29%
Depreciation, Depletion And Amortization $32.00K $19.00K
YoY Change 68.42% 137.5%
Cash From Operating Activities $17.43M -$8.350M
YoY Change -308.74% 38.94%
INVESTING ACTIVITIES
Capital Expenditures $109.0K $200.0K
YoY Change -45.5% 40.89%
Acquisitions
YoY Change
Other Investing Activities -$84.85M $3.610M
YoY Change -2450.42% -34.36%
Cash From Investing Activities -$84.96M $3.410M
YoY Change -2591.5% -36.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00K
YoY Change -99.96%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 61.18M 50.00K
YoY Change 122260.0% -99.95%
NET CHANGE
Cash From Operating Activities 17.43M -8.350M
Cash From Investing Activities -84.96M 3.410M
Cash From Financing Activities 61.18M 50.00K
Net Change In Cash -6.350M -4.890M
YoY Change 29.86% -104.65%
FREE CASH FLOW
Cash From Operating Activities $17.43M -$8.350M
Capital Expenditures $109.0K $200.0K
Free Cash Flow $17.32M -$8.550M
YoY Change -302.58% 38.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
10896000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10896000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-10695000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
26046000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26046000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-25798000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36873594
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20030129
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25824000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-144000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-135000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5980000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
100160000
CY2015Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
96000
CY2016Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
14000
CY2015Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
105000
CY2016Q1 us-gaap Depreciation
Depreciation
32000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1251000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1128000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
801000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
102000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2308000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1457000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-411000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
40000000
CY2015Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-30000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8347000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
200000
CY2015Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
9585000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-84955000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3405000
CY2016Q1 akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
61166000
CY2015Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
50000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
CY2016Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3000
CY2015Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
61182000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6339000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4893000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32780000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27887000
CY2016Q1 akba Deferred Follow On Offering Issuance Costs
DeferredFollowOnOfferingIssuanceCosts
20000
CY2015Q1 akba Deferred Follow On Offering Issuance Costs
DeferredFollowOnOfferingIssuanceCosts
55000
CY2015Q1 akba Assets Acquired Under Capital Leases
AssetsAcquiredUnderCapitalLeases
12000
CY2016Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
234000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10703000
CY2015Q1 us-gaap Depreciation
Depreciation
19000
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
188000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
17434000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
15314000
CY2015Q4 akba Accrued Clinical Current
AccruedClinicalCurrent
4536000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1043000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, stock-based compensation expense, accrued expenses and income taxes. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair market value of its common stock as determined by the Board of Directors contemporaneously at the date such grants were made, with input from management. Prior to the Company&#8217;s IPO in March&#160;2014, the fair value of common stock at the grant date was adjusted in connection with the Company&#8217;s retrospective fair value assessment for financial reporting purposes. Accordingly, the Board of Directors determined the estimated fair value of the Company&#8217;s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time and the likelihood of achieving a liquidity event, such as an IPO or sale of the Company.&nbsp;&nbsp;</p></div>
CY2016Q1 akba Cash Cash Equivalents And Short Term Investments Fair Value Disclosure
CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure
217025000
CY2016Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2015Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and investments are the only financial instruments that potentially subject the Company to concentrations of credit risk. The Company maintains its cash with high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</p></div>
CY2016Q1 us-gaap Revenues
Revenues
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
808000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
687000
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
179000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
147000
CY2016Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43439000
CY2016Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
217052000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
122978000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
50608000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
173586000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
88910000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
235000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
49778000
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
138688000
CY2015Q4 akba Cash Cash Equivalents And Short Term Investments Fair Value Disclosure
CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure
138454000
CY2016Q1 akba Accrued Clinical Current
AccruedClinicalCurrent
6998000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
647000
CY2016Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
679000
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2178000
CY2016Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
425000
CY2015Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
310000
CY2016Q1 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
319000
CY2016Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
218000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
518000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1312000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1366000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5511806
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4206809
CY2016Q1 akba Allocated Share Based Compensation Expense Reversal
AllocatedShareBasedCompensationExpenseReversal
1251000
CY2015Q1 akba Allocated Share Based Compensation Expense Reversal
AllocatedShareBasedCompensationExpenseReversal
1128000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P3Y
CY2013Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
6837
CY2013Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
31000
CY2013Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
31000
CY2013Q4 akba Lease Commencement Period
LeaseCommencementPeriod
2014-01
CY2013Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
125345
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8530
CY2014Q4 akba Lease Space Occupancy Date
LeaseSpaceOccupancyDate
2015-03-13
CY2016Q1 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
32000
CY2014Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
45000
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-12-31
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
100000
CY2014Q4 us-gaap Security Deposit
SecurityDeposit
179130
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2140000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3121000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3121000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3121000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
3121000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
17685000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
32309000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
9000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
9000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
5000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
23000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1000
CY2016Q1 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
22000
CY2016Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
2149000
CY2016Q1 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
3130000
CY2016Q1 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
3126000
CY2016Q1 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
3121000
CY2016Q1 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
3121000
CY2016Q1 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
17685000
CY2016Q1 us-gaap Contractual Obligation
ContractualObligation
32332000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2015Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2016Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
13700000
CY2015 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
5200000
CY2016Q1 akba Purchase Committed Program Remaining Contract Costs
PurchaseCommittedProgramRemainingContractCosts
238800000
CY2016Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2015Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016Q1 akba Defined Contribution Plan Employees Age To Be Eligible Under Plan
DefinedContributionPlanEmployeesAgeToBeEligibleUnderPlan
P21Y
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2307993

Files In Submission

Name View Source Status
0001564590-16-017968-index-headers.html Edgar Link pending
0001564590-16-017968-index.html Edgar Link pending
0001564590-16-017968.txt Edgar Link pending
0001564590-16-017968-xbrl.zip Edgar Link pending
akba-10q_20160331.htm Edgar Link pending
akba-20160331.xml Edgar Link completed
akba-20160331.xsd Edgar Link pending
akba-20160331_cal.xml Edgar Link unprocessable
akba-20160331_def.xml Edgar Link unprocessable
akba-20160331_lab.xml Edgar Link unprocessable
akba-20160331_pre.xml Edgar Link unprocessable
akba-ex311_6.htm Edgar Link pending
akba-ex312_7.htm Edgar Link pending
akba-ex321_8.htm Edgar Link pending
akba-ex991_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gen21ym2tkji000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending